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Abstract 
Insulin resistance is defined as a glucose homeostasis disorder involving a decreased sensitivity of muscles, adipose tissue, liver and other 
body tissues to insulin, despite its normal or increased concentration in blood.
Insulin resistance may be asymptomatic or occur presenting a variety of disorders, such as: glucose tolerance impairment, type 2 diabetes, 
as well as hypercholesterolaemia, hypertriglyceridaemia, obesity, and arterial hypertension.
Insulin acts via specific receptors present on the surface of most cells of the body. The greatest number of these receptors is found on 
adipocytes, hepatocytes and striated muscle cells. 
There are three mechanisms of insulin resistance: pre-receptor, receptor and post-receptor.
Multiple methods of assessing insulin resistance are based on the concurrent measurements of glucose and insulin levels in blood serum. 
The glucose and insulin measurements are conducted in baseline conditions or after intravenous administration of a specific quantity of 
glucose or insulin. The methods of assessing insulin resistance are divided into direct and indirect. 
The current ‘gold standard’ in the assessment of insulin sensitivity is the determination of tissue glucose utilisation using the metabolic 
clamp technique.
The presence of disorders of carbohydrate metabolism has been demonstrated in thyroid disease involving either overt hyperthyroidism 
or overt hypothyroidism. The severity of the disease is proportional to the severity of these disorders. The possible influence of subclinical 
forms of both hyperthyroidism and hypothyroidism on carbohydrate disorders is still under discussion.
Thyroid hormones have a significant effect on glucose metabolism and the development of insulin resistance. In hyperthyroidism, impaired 
glucose tolerance may be the result of mainly hepatic insulin resistance, whereas in hypothyroidism the available data suggests that the 
insulin resistance of peripheral tissues prevails. (Endokrynol Pol 2014; 65 (1): 70–76)
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Streszczenie
Insulinooporność definiuje się jako zaburzenie homeostazy glukozy polegające na zmniejszonej wrażliwości mięśni, tkanki tłuszczowej, 
wątroby oraz innych tkanek na insulinę pomimo jej prawidłowego lub podwyższonego stężenia we krwi. Insulinooporność może prze-
biegać bezobjawowo lub towarzyszyć różnorodnym chorobom i zaburzeniom, takim jak upośledzona tolerancja glukozy, cukrzyca typu 
2, hipercholesterolemia, hipertriglicerydemia, otyłość i nadciśnienie tętnicze.
Insulina działa za pośrednictwem swoistych receptorów obecnych na powierzchni większości komórek organizmu. Najwięcej tych re-
ceptorów stwierdza się na komórkach tłuszczowych, hepatocytach i komórkach mięśni poprzecznie prążkowanych. 
Wyróżnia się trzy rodzaje insulinooporności: przedreceptorową, receptorową i poreceptorową.
Metody rozpoznawania insulinooporności oparte są na jednoczesnym oznaczaniu stężenia glukozy i insuliny w surowicy krwi. Pomiary 
stężenia glukozy i insuliny wykonywane są albo w warunkach podstawowych, albo po dożylnym podaniu określonej ilości glukozy lub 
insuliny. Metody oceny insulinooporności można podzielić na bezpośrednie i pośrednie.
Obecnie za „złoty standard” w ocenie insulinowrażliwości uważa się pomiar zużycia glukozy przez tkanki metodą euglikemicznej klamry 
metabolicznej.
Występowanie zaburzeń gospodarki węglowodanowej wykazano w chorobach tarczycy przebiegających z jawną nadczynnością lub 
jawną niedoczynnością. Nasilenie zaburzeń gospodarki węglowodanowej jest proporcjonalne do nasilenia zaburzeń czynności tarczycy. 
Nadal toczą się dyskusje na temat ewentualnego wpływu podklinicznych postaci nadczynności i niedoczynności tarczycy na zaburzenia 
gospodarki węglowodanowej.
Hormony tarczycy wywierają istotny wpływ na metabolizm glukozy i rozwój insulinooporności. W nadczynności tarczycy upośledzona 
tolerancja glukozy może być konsekwencją przede wszystkim insulinooporności wątrobowej, natomiast w przypadku niedoczynności 
tarczycy z dostępnych danych wynika, że dominującą komponentą insulinooporności jest insulinooporność tkanek obwodowych. (En-
dokrynol Pol 2014; 65 (1): 70–76)
Słowa kluczowe: insulinooporność, choroby tarczycy, nadczynność tarczycy, niedoczynność tarczycy
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Abbreviations
VLDL — very low density lipoprotein 
GLUT — glucose transporter
HO — hypothyroidism 
SHO — subclinical hypothyroidism
HR — hyperthyroidism
SHR — subclinical hyperthyroidism
fT3 — free triiodotyronine
fT4 — free tetraiodotyronine
TSH — tyreothropin
BMI — Body Mass Index
HOMA-IR — Homeostatic Model Assessment-Index 
OGTT — oral glucose tolerance test 
QUICKI — Quantitative Insulin Sensitivity Check Index 
IgG — immunoglobulin G
PEPCK — phosphoenolpyruvate carboxykinase
TNF — tumour necrosis factor 
Introduction
Insulin resistance is defined as a glucose homeostasis 
disorder involving a decreased sensitivity of muscles, 
adipose tissue, liver and other body tissues to insulin, 
despite its normal or increased concentration in blood 
[1, 2].
Insulin resistance may be asymptomatic or occur 
presenting a variety of disorders, such as: glucose 
tolerance impairment, type 2 diabetes, as well as hy-
percholesterolaemia, hypertriglyceridaemia, obesity, 
and arterial hypertension.
Mechanisms of insulin resistance
Insulin acts via specific receptors present on the surface 
of most cells of the body (Fig. 1). The greatest number 
of these receptors is found on adipocytes, hepatocytes 
and striated muscle cells.
An insulin receptor is a heterodimer composed 
of two alpha-subunits, located extracellularly, and 
two beta-subunits, transmembrane proteins. The cy-
toplasmic part of the beta-subunit is endowed with 
tyrosine kinase activity and contains a region with 
autophosphorylation capability. Once insulin binds to 
the alpha-subunit, autophosphorylation of the beta-
subunit occurs, which leads to the release of one or 
several signals triggering a pathway of cellular response 
to the hormone and internalisation of the receptor (its 
translocation into the cell interior). 
There are three mechanisms of insulin resistance: 
pre-receptor, receptor and post-receptor, all of which 
are presented in Table I [1, 2].
Insulin resistance is distinguished into peripheral 
and hepatic. The peripheral type of insulin resistance 
develops in skeletal muscles and adipose tissue, and is 
Table I. Insulin resistance mechanisms
Tabela I. Mechanizmy oporności na insulinę
Pre-receptor Receptor Post-receptor
Genetic abnormalities in the structure of insulin  
molecules (the so-called ‘mutant insulin syndrome’)
Decreased number of  
insulin receptors
Abnormalities in the processes signalling 
the binding of insulin to the insulin receptor 
(intracellular signal transduction disorders)
Increased degradation of insulin Lower affinity of insulin  
receptors to insulin  
(due to mutations)
Abnormalities in the structure and function 
of glucose transporters carrying glucose into 
the cell
Presence of antibodies (IgG) binding normal insulin  
molecules in blood
Increased lipolysis leading to higher quantity 
of free fatty acids, whose excessive 
oxidation is responsible for inhibiting 
glycolysis
Presence of substances or hormones acting as insulin antagonists 
in blood: cortisol, glucagon, growth hormone, thyroid hormone, 
androgens
Figure 1. Structure and function of insulin receptor (following [1])
Figure 1. Struktura i funkcja receptora insuliny (wg [1])
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characterised by abnormalities in glucose uptake and 
utilisation by muscle tissue, as well as increased lipolysis 
in adipose tissue followed by an increased release of 
free fatty acids. The hepatic type of insulin resistance 
involves increased glycogenolysis and gluconeogenesis, 
as well as production of the VLDL fraction of cholesterol 
and triglycerides by hepatocytes.
Insulin resistance in thyroid disease
Normal glucose metabolism may be disrupted by either 
a deficit or an excess of thyroid hormones, leading to 
carbohydrate disorders (Fig. 2).
Insulin receptors on monocytes quickly respond 
to changes in blood serum glucose levels and rapidly 
increase the glucose elimination rate in the presence of 
glucose [3–5]; therefore the cells may constitute a read-
ily available and reliable model for metabolic studies.
Moreover, monocytes exhibit the expression of 
all isoforms of glucose transporter (GLUT) on their 
plasma membrane, found either in muscle or adipose 
tissues; increased glucose transport in response to the 
higher glucose levels in those cells correlates with that 
observed in tissues that are quantitatively significant 
for glucose elimination [3, 4].
In the study by Maratou et al., patients with overt 
hypothyroidism (HO) and subclinical hypothyroidism 
(SHO) presented a decreased level of insulin-stimulated 
glucose transport in monocytes due to disrupted trans-
location of the GLUT4 — glucose transporter in the 
plasma membrane [6].
Patients with overt hyperthyroidism (HR) and sub-
clinical hyperthyroidism (SHR) in the study by Maratou 
et al. [4] also presented an increased level of baseline 
density of the GLUT4 and GLUT3 receptors. This is in 
line with the results of earlier studies in patients with 
HR [5, 7]. The increased expression of the GLUT3 and 
GLUT4 glucose transporters at the baseline insulin 
levels reflects the ability of monocytes to ‘cope’ with 
the increased rate of metabolism associated with this 
condition [4].
Another potential pathogenetic mechanism of the 
development of insulin resistance in hypothyroidism 
is associated with a decreased blood flow in peripheral 
tissues [8].
Assessing insulin resistance
Multiple methods of assessing insulin resistance (Table II) 
are based on the concurrent measurements of glucose 
and insulin levels in blood serum [1]. The glucose and 
insulin measurements are conducted in baseline condi-
tions or after intravenous administration of a specific 
quantity of glucose or insulin. The methods of assessing 
insulin resistance are divided into direct and indirect. 
The current ‘gold standard’ in the assessment of 
insulin sensitivity is the determination of tissue glucose 
utilisation using the metabolic clamp technique. The 
method involves quantification of glucose that needs 
to be administered to the patient to maintain a con-
stant glycaemia during a 120-minute insulin infusion. 
The administered quantity of glucose corresponds to 
its utilisation in tissues and therefore, indirectly, their 
Figure 2. Effect of thyroid hormones on glucose metabolism in patients with euthyreosis, hyperthyroidism and hypothyroidism
Rycina 2. Wpływ hormonów tarczycy na metabolizm glukozy u pacjentów z eutyreozą, nadczynnością tarczycy i 
niedoczynnością tarczycy
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insulin sensitivity. Lower doses of glucose necessary to 
maintain a constant glycaemia indicate greater insulin 
resistance. Unfortunately, due to the complex and time-
consuming procedure employed, the method is used in 
clinical studies rather than population studies.
Another direct method is the insulin tolerance test. 
This involves administration of a single insulin dose of 
0.1 U/kg body weight followed by the measurement of 
blood serum glucose levels. In subjects with insulin re-
sistance, the decrease in blood glucose levels is insignifi-
cant, while in insulin-sensitive subjects, blood glucose 
levels decrease to 50% of the baseline glycaemia value.
The endogenous insulin suppression test involves 
inhibition of the secretion of endogenous insulin by 
administering adrenalin and propranolol. In insulin-
sensitive subjects, the glucose levels obtained in the test 
are within the normal range, while in subjects with in-
sulin resistance, higher glycaemia values are observed. 
In epidemiological studies, insulin resistance is as-
sessed using estimates determined from fasting glycae-
mia and insulinaemia values or using the oral glucose 
challenge test [9].
The most straightforward method is the determi-
nation of the quotient of insulin and glucose levels in 
blood serum. Values above 0.3 are indicative of insulin 
resistance.
Currently, a mathematical model of assessing insulin 
resistance (HOMA, Homeostatic Model Assessment) is 
widely used. The insulin resistance index is determined 
from glucose and insulin levels in blood in baseline 
conditions, according to the following formula: 
HOMA-IR (mmol/L × μU/mL) = fasting glucose 
levels × fasting insulin levels/22.5. The physiological 
value of the index is 1.0. Higher values are indicative 
of insulin resistance.
QUICKI (Quantitative Insulin Sensitivity Check 
Index) is determined according to the following for-
mula: 1/(log fasting insulinaemia (μU/mL) + log fasting 
glycaemia (mmol/L). Values < 0.34 are indicative of 
insulin resistance.
Matsuda index is determined using the following 
formula: 100,000/fasting insulinaemia (μU/mL) × fasting 
glycaemia (mg/dL) × mean glycaemia value in the Oral 
Glucose Tolerance Test (OGTT) × mean insulinaemia 
value in OGTT. Values < 7.3 are indicative of insulin 
resistance [2,9].
The intravenous glucose tolerance test involves 
administration of glucose at the dose of 0.33 g/kg b.w. 
in a fast intravenous infusion with concurrent meas-
urements of blood serum glucose levels (immediately 
before the test starts and every ten minutes in the first 
hour of the test). In this way, the tissue glucose assimi-
lation index (K) may be determined, which indicates 
the percentage of glucose that will be depleted from 
the extracellular space in one minute. Normal values 
of the K index are within the range 1.5–2.5. Values < 
1.5 combined with increased or normal plasma insulin 
levels are indicative of insulin resistance.
The double intravenous glucose challenge test in-
volves i.v. administration of glucose at the dose of 0.33 
g/kg b.w. in a fast intravenous infusion with concurrent 
measurements of blood serum glucose levels (immedi-
ately before the test starts and every ten minutes in the 
first hour of the test), and then repeating this procedure 
with an additional infusion of insulin at the dose of 
0.1 U/kg b.w. The difference between the tissue glucose 
assimilation indices K1 and K2 provides information on 
the function of endogenous insulin.
The Bergman method involves intravenous admin-
istration of glucose at the dose of 0.3 g/kg b.w. which, 
20 minutes later, is followed by an i.v. administration 
of tolbutamide (dosage depends on body weight) that 
activates the secretion of endogenous insulin [2, 10]. 
The test duration is three hours. During that time, 
insulinaemia and glycaemia in venous blood are deter-
mined 26 times. The obtained results, along with the 
mathematical model proposed by Bergman, permit the 
determination of the tissue insulin sensitivity index.
By comparing the HOMA-IR, Quicki and Matsuda 
indices, Szurkowska et al. established that the indices 
had a similar predictive value in diagnosing metabolic 
syndrome in the group of subjects with normal glucose 
tolerance. However, in the group of subjects with im-
paired glucose tolerance, the Matsuda index presents 
the greatest value [9]. 
The clinical outcomes of insulin resistance primarily 
include: metabolic syndrome, type 2 diabetes, cardio-
vascular disease, nonalcoholic steatohepatitis, obstruc-
tive sleep apnoea, and polycystic ovary syndrome.
Insulin resistance and hormonal disorders
Most hormones decrease the effect of insulin in the 
organism at the level of the liver (increased glucose 
Table II. Methods of assessing insulin resistance
Tabela II. Metody oceny insulinooporności
Direct methods Indirect methods
1. Metabolic clamp technique  
— the ‘gold standard’
2. Insulin tolerance test
3. Endogenous insulin  
suppression test
1. Insulinaemia/glycaemia index
2. HOMA-IR index
3. Quicki index
4. Matsuda index
5. Intravenous glucose tolerance test
6. Double intravenous glucose 
challenge test
7. Bergman method
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production) and peripheral tissues (decreased glucose 
utilisation) [11]. Among the hormones whose excess 
is the most common cause of carbohydrate disorders 
are: growth hormone, glucocorticosteroids, tyroxine, 
catecholamines, parathormone, aldosterone, as well as 
glucagon and somatostatin. Their activity induces hy-
perinsulinaemia as a result of a compensatory increase 
in insulin secretion in response to the higher insulin 
resistance and of a direct stimulation of pancreatic 
b-cells by antagonistic hormones [2, 11] (Table III). 
Insulin resistance and thyroid disease
The presence of disorders of carbohydrate metabolism 
has been demonstrated in thyroid disease involving 
either overt hyperthyroidism or overt hypothyroid-
ism [9]. The severity of the disease is proportional to 
the severity of these disorders. The possible influence 
of subclinical forms of both hyperthyroidism and hy-
pothyroidism on carbohydrate disorders is still under 
discussion [9, 10, 12]. 
Hyperthyroidism
Hyperthyroidism is a condition characterised by an 
increase in the blood serum levels of thyroid hormones 
and their effect on tissues [9]. The condition involves 
a significant increase in the level of tissue metabolism. In 
order to adapt to the greater energy loss, both baseline 
and insulin-stimulated rate of cellular glucose depletion 
increases as a result of the more intense glucose oxidation 
and lactic acid formation, the latter of which is subse-
quently used by the liver to accelerate gluconeogenesis 
and the production of endogenous glucose [4, 13].
Clinical hyperthyroidism (HR) is often accompanied 
by abnormal glucose tolerance and insulin resistance [4, 
13–15]. In approximately 50% of patients with hyper-
thyroidism, glucose tolerance disorders were observed, 
and 2–3% of patients had diabetes. In non-diabetic 
subjects, normal or increased fasting insulin, peptide 
C and proinsulin concentrations are observed, which is 
indicative of moderate peripheral insulin resistance [9]. 
This is associated with an increased insulin resistance 
in the liver, aggravation of general peripheral insulin 
resistance, and increased glucose uptake in muscles. 
Overt hyperthyroidism increases the demand for 
insulin. It is associated with accelerated metabolism, 
tissue resistance to insulin and increased insulin degra-
dation. In thyrotoxicosis, increased glucose absorption 
occurs in the digestive tract thanks to a higher rate of 
stomach emptying and increased blood flow in the por-
tal vein, which leads to postprandial hyperglycaemia, 
characteristic of hyperthyroidism [16].
The effect of thyroid hormones on hepatocytes is an-
tagonistic to insulin and stimulates glucose production 
in the liver (increases gluconeogenesis and glycogenoly-
sis). In the conducted studies, it was demonstrated that 
thyrotoxicosis increases the production of endogenous 
glucose in the liver in baseline conditions (fasting state) 
and decreases the hepatic sensitivity to insulin. Ob-
servations indicate that thyroid hormones may have 
both a direct and an indirect effect on hepatic cells. The 
direct effect is achieved via alteration of transcription 
and translation of the genes responsible for gluconeo-
genesis and glycogen metabolism. Another mechanism 
by which thyroid hormones stimulate hepatic glucose 
production is based on the increased expression of 
the GLUT2 glucose transporter on hepatocyte plasma 
membranes. The indirect effect is achieved by increas-
ing the activity of the parasympathetic nervous system, 
modulated by the hypothalamus, and its influence on 
hepatocytes [17]. 
Moreover, thyroid hormones promote lipolysis, 
thereby increasing the concentration of free fatty ac-
ids in blood and accelerating insulin degradation. In 
thyrotoxicosis, the high levels of triiodothyronine (fT3) 
directly stimulate gluconeogenesis as a result of the 
increased activity of PEPCK (phosphoenolpyruvate 
carboxykinase).
In subjects with hyperthyroidism, lower periph-
eral tissue sensitivity to insulin and abnormal insulin 
secretion are also responsible for glucose metabolism 
disorders. Explaining the effect of hyperthyroidism on 
glucose utilisation in peripheral tissues is difficult due to 
the complexity of the problem. On the one hand, it was 
observed that the glucose uptake rate in peripheral tis-
sues is increased by thyroid hormones, which suggests 
that glucose utilisation is considerably higher, especially 
Table III. Effect of hormones on insulin secretion and 
carbohydrate metabolism
Tabela III. Wpływ na wydzielanie insuliny, hormonów 
i metabolizmu węglowodanów
Hormone Insulin  
secretion
Hepatic glucose 
production
Growth hormone + +
Cortisol + +
Tyroxine ? +
Catecholamines – +
Aldosterone – +
Glucagon + +
Somatostatin – ?
Parathormone – +
Prolactin + ?
+ activation, – inhibition, ? effect unconfirmed
75
Endokrynologia Polska 2014; 65 (1)
in skeletal muscles. This increased glucose utilisation 
is caused mainly by the higher level of glucose oxida-
tion stimulated by insulin. On the other hand, it has 
also been observed that anaerobic glucose metabolism 
stimulated by insulin is inhibited, as glycogenogenesis 
decreases due to the ‘redirection’ of intracellular glucose 
to the process of glycolysis and generation of lactic acid. 
The lactic acid released from peripheral cells returns to 
the liver, where it becomes a substrate for the increased 
hepatic glucose production. The occurrence of glucose 
intolerance associated with hyperthyroidism may be ex-
plained simply by the hepatic type of insulin resistance. 
However, in some studies, impaired peripheral glucose 
uptake stimulated by insulin was demonstrated.
Alternatively, peripheral insulin resistance in hyper-
thyroidism may be explained by the increased secretion 
of bioactive mediators (adiponectins), such as interleu-
kin-6 and TNF-alpha, by adipocytes. Higher levels of 
these adiponectins have been observed in women with 
hyperthyroidism [18].
It is observed that in hyperthyroidism, blood in-
sulin levels may be lower, normal or even higher. Yet 
the results of different studies indicating an increased 
degradation of insulin in hyperthyroidism are quite 
consistent. It is also suggested that in long-term severe 
thyrotoxicosis, irreversible damage to the pancreas 
may occur. 
Subclinical hyperthyroidism (SHR) is defined as 
decreased TSH levels accompanied by normal levels 
of fT3 and fT4. Among the studies conducted to date, 
those regarding insulin resistance in SHR are few and 
their results are controversial. Adamczyk et al. only 
observed a  weak impairment of insulin sensitivity 
that was associated with the lower activity of plasma 
paraoxonase [9, 19]. Other authors, in their papers 
on iatrogenic SHR, describe a lower or unchanged 
level of insulin sensitivity. Endogenous subclinical 
hyperthyroidism, compared to the exogenous type, 
may have a greater effect on glucose metabolism as 
a result of the chronic nature of the disease and the 
observed higher T3 levels [20]. 
In their study, Maratou et al. [16] determined the 
presence of insulin resistance in both clinical and sub-
clinical types of hyperthyroidism. The increased HOMA 
index and the decreased Matsuda and Belfiore indices 
in patients with HR and SHR, compared to euthyreoid 
patients, suggest that insulin resistance is present in 
either fasting or postprandial state. Similar results were 
presented in the papers by Yavuz et al. [19, 21], who 
observed a significantly lower insulin sensitivity in the 
SHR group. Similar results were presented by Roos et al. 
[22] who also determined that insignificantly (slightly) 
lower levels of thyroid hormones within the physiologi-
cal range negatively correlate with the HOMA index. 
This suggests that even small deviations from thyroid 
hormone balance may lead to insulin resistance [4, 22].
Hypothyroidism 
Clinical hypothyroidism (HO) is considered to be an 
insulin resistance risk factor [6, 8, 23–26]. In hypothy-
roidism, a decrease in the intestinal glucose absorption 
rate occurs, along with a decrease in the adrenergic ac-
tivity leading to a reduction in liver and muscle glycog-
enolysis, as well as a decrease in gluconeogenesis and 
baseline insulin secretion [6, 9]. However, a postprandial 
increase in insulin secretion against the background 
of generalised peripheral insulin resistance has been 
observed, associated with a higher concentration of 
free fatty acids, reduced glucose uptake and increased 
glucose oxidation [9].
There are fewer studies of the effect of hypothyroid-
ism on glucose metabolism than those assessing insulin 
resistance in patients with hyperthyroidism.
Rochon et al. determined the sensitivity of all tis-
sues to insulin in patients with hypothyroidism. The 
metabolic clamp technique was used in their study. 
They concluded that hypothyroidism causes a decrease 
in insulin-dependent glucose utilisation, which may be 
reversed via appropriate treatment [23]. Similar results 
were obtained by Stanicka et al. [27]. Handisurya et al. 
also confirmed the above results by assessing insulin 
resistance via the metabolic clamp technique, as well 
as assessing glucose tolerance and the activity of pan-
creatic beta-cells during an oral glucose tolerance test 
[10]. Dimitriadis et al. investigated glucose uptake by 
skeletal muscles and adipose tissue in subjects with 
hypothyroidism and a control group. Reduced ability 
of insulin to increase blood flow in tissues in hypo-
thyroidism was observed. This may be an alternative 
mechanism explaining the effect of hypothyreosis on 
decreasing glucose utilisation by peripheral cells [8]. 
Brenta et al. observed that patients with hypothyroid-
ism, compared to euthyreotic subjects, demonstrated 
a significantly lower glucose utilisation during a short 
intravenous insulin tolerance test [28].
However, there are studies that do not confirm the 
above observations. Owecki et al. did not demonstrate 
any correlation between hypothyroidism and insulin 
sensitivity in patients with overt hypothyroidism, based 
on the assessment of the HOMA-IR index [29].
Subclinical hypothyroidism (SHO) is defined as 
increased TSH levels in blood plasma accompanied by 
normal plasma levels of thyroid hormones (fT3, fT4) [9]. 
The data on the effect of insulin on glucose metabolism 
in this disease is ambiguous.
In their study, Maratou et al. suggested that insulin 
resistance not only affects patients with HO, but also 
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those with SHO. In both studied groups (HO and SHO) 
of overweight patients of average age 50 years (with 
average BMI of approximately 26 kg/m2), compared 
to euthyreoid patients, increased HOMA index score 
and decreased Matsuda index score were detected [6]. 
These results are in line with other studies in 
patients with hypothyroidism [30–32]. Interestingly, 
a positive correlation between thyroid hormones and 
Matsuda index has been found, which suggests that 
lower levels of thyroid hormones lead to a lower sen-
sitivity of tissues to insulin [6]. 
The lower fasting insulin sensitivity assessed using 
the HOMA index was also found lower in a number 
of other studies in patients with SHO [4, 10, 33]. Yet, 
the results of other studies indicate a normal insulin 
sensitivity in that group of patients [34, 35]. 
However, it should be noted that in some of these 
studies in which insulin resistance was not found in 
patients with SHO, fasting hyperinsulinaemia was re-
ported [33, 36]. These observations may be interpreted 
as an early sign of impairment of glucose metabolism.
Conclusions
Thyroid hormones have a significant effect on glucose 
metabolism and the development of insulin resistance. 
In hyperthyroidism, impaired glucose tolerance may be 
the result of mainly hepatic insulin resistance, whereas 
in hypothyroidism, the available data suggests that the 
insulin resistance of peripheral tissues prevails. 
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